Reforgene named a Top 10 China medical innovation company 2021
On October 12, 2021, the "CHS 2021 Sixth China Big Health Industry Upgrade Summit" and awards dinner, hosted by the General Practice Medicine and Health Management Committee of the China Health Information and Healthcare Big Data Society and EqualOcean, and guided by the Sichuan Provincial Health Commission and the China Health Information and Healthcare Big Data Society, was grandly held in Chengdu. The "2021 China Big Health Industry Integrated Innovation List" was officially released.
Among them, the widely watched "2021 China Top 10 Medical Innovation Enterprises" was unveiled. The list aims to identify domestic hard technology enterprises representing the future direction. After intense competition and evaluation, Reforgene stood out with its rapid growth and technological innovation strength in the gene editing medicine field in recent years, and was listed among the "2021 China Top 10 Medical Innovation Enterprises".
Background
The China Big Health Industry Upgrade Summit has been successfully held for five editions. This edition, themed "Integrated Innovation, Leading Industrial Convergence", discussed topics around market environment, investment hotspots and industrial transformation in seven sub-fields including digital healthcare, AI- and computing-driven new drug R&D, primary care, payment innovation and genetic testing.
From an industry-wide perspective, driven by new technologies and new models, the big health industry is developing rapidly in a diversified ecosystem with multiple dimensions, continuously upgrading and innovating, and sub-fields are breaking down boundaries and barriers, showing a trend of convergence. As an observer and recorder deeply engaged in the big health industry, EqualOcean Health has been committed to discovering the emerging forces in the industry and helping the upgrading of the big health industry.
The evaluation criteria of this award not only took into account hard indicators such as enterprise founding time, financing rounds and operating conditions, but also considered multiple soft factors, including the prospects of the track the enterprise is in, the clarity of the project's business model, the innovativeness of the project, the obviousness of product differentiation, product or service quality, the strength of brand awareness, and business growth speed, fully understanding and accommodating the survival conditions of enterprises in the context of the COVID-19 pandemic.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.